Bioadvance Capital
Fiscal year ending 2024. Filed on April 30, 2025.
101 West Elm Street 330
Conshohocken, Pennsylvania 19428
Bioadvance Capital (EIN: 46-0481876) has filed an IRS Form 990 since at least fiscal year 2016. In its fiscal year 2024 IRS Form 990 filing, Bioadvance Capital, a 501(c)(3) charitable organization, reported compensation for 6 out of 6 total employees. Among the employees shown here, the average compensation is $247,867. The highest compensated employee at Bioadvance Capital is Frederick Jones with fiscal year 2024 compensation of $405,243. Bioadvance Capital changed its name from Bioadvance Dba the Biotechnology Greenhouse of Southeastern Pennsylvania in 2024.
Revenue, expenses, and employee compensation
Revenue
Expenses
Employee compensation
Reported Compensated Employees
Mission Statement
BIOADVANCE WAS ESTABLISHED IN 2001 AS ONE OF THREE LIFE SCIENCES GREENHOUSES FUNDED WITH A SHARE OF PENNSYLVANIA'S NATIONAL TOBACCO SETTLEMENT REVENUES, TO PROMOTE HUMAN HEALTH BY SUPPORTING BIOMEDICAL INNOVATION IN THE SOUTHEASTERN PA REGION. BIOADVANCE DEDICATED $25 MILLION OF THE ORIGINAL GRANT FUNDING FOR PRE-SEED AND EARLY-STAGE FUNDING TO HELP MOVE TECHNOLOGIES TO THE NEXT STAGE OF DEVELOPMENT AND TO SUPPORT THE INITIATIVES INTENDED TO INCREASE THE REGION'S STRENGTH IN BIOMEDICAL INFORMATICS AND CLINICAL TRIALS. SINCE THE ORIGINAL GRANT FUNDING WAS EXPENDED, BIOADVANCE CONTINUES TO SUPPORT EMERGING LIFE SCIENCES COMPANIES IN SOUTHEASTERN PA AND THE SURROUNDING MID-ATLANTIC REGION THAT ARE FOCUSED ON TECHNOLOGIES TO IMPROVE HUMAN HEALTH. AS OF JUNE 30, 2024, A TOTAL OF $72.7 MILLION HAS BEEN INVESTED BY BIOADVANCE IN 114 COMPANIES AND ACADEMIC TECHNOLOGIES.
Revisions to this organization profile
Get an email when new compensation information is released for Bioadvance Capital
Be the first to know when new IRS Form 990 data is published for this organization.